- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05727176
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement (FOENIX-CCA4)
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements
Study Overview
Status
Intervention / Treatment
Detailed Description
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements. Eligible patients will be randomized on a 1:1 basis to the following study arms:
- Patients will receive futibatinib at an oral dose of 16 mg, administered daily (QD) on every day of a 21-day cycle.
- Patients will receive futibatinib at an oral dose of 20 mg, administered daily (QD) on every day of a 21-day cycle.
Patients may continue to receive continuous futibatinib until documentation of progressive disease (PD) per RECIST 1.1, or until other withdrawal criteria are met, whichever comes first.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Expanded Access
Contacts and Locations
Study Contact
- Name: Taiho Oncology, INC
- Phone Number: 609-250-7336
- Email: clinicaltrialinfo@taihooncology.com
Study Locations
-
-
-
Caba, Argentina, 1431
- Not yet recruiting
- Cemic
-
Contact:
- Phone Number: +54 5299-0100
- Email: julieta.grasselli@gmail.com
-
Principal Investigator:
- Julieta Grasselli
-
Ciudad Autonoma de Buenos Aires, Argentina, AEB1280
- Not yet recruiting
- Hospital Britanico
-
Contact:
- Phone Number: +54 4309-6400
- Email: lubq1@yahoo.com.ar
-
Principal Investigator:
- Luciana Bella Quero
-
Rosario, Argentina, S2013
- Not yet recruiting
- Sanatorio de la Mujer
-
Contact:
- Phone Number: +54 640-5260
- Email: cristina_nasurdi@hotmail.com
-
Principal Investigator:
- Cristina Nasurdi
-
-
-
-
-
Sydney, Australia, 2010
- Not yet recruiting
- St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
-
Principal Investigator:
- Hao-Wen Sim
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Not yet recruiting
- Alfred Health, Medical Oncology Unit, Second floor William Buckland Radiotherapy Center
-
Principal Investigator:
- Sanjeev Gill
-
-
-
-
-
Cerqueira César, Brazil, 01246-000
- Not yet recruiting
- Instituto do Cancer do Estado de São Paulo
-
Contact:
- Phone Number: +55 11 9 9644-6112
- Email: marlene.salgado@hc.fm.usp.br
-
Principal Investigator:
- Camila Motta Venchiarutti Moniz
-
Curitiba, Brazil, 80530-010
- Not yet recruiting
- IOP - Instituto de Oncologia do Parana
-
Contact:
- Phone Number: +55 3207-9788
- Email: mariana.brandao@iop.com.br
-
Principal Investigator:
- Luciano Semensato Biela
-
Curitiba, Brazil, 81520-060
- Not yet recruiting
- Hospital Erasto Gaertner
-
Contact:
- Phone Number: +55 3361-5195
- Email: andressaschuta@gmail.com
-
Principal Investigator:
- Andressa Ribas
-
São José Do Rio Preto, Brazil, 15090-000
- Not yet recruiting
- Hospital de Base de Sao Jose do Rio Preto
-
Contact:
- Phone Number: + 55 3201-5054
- Email: caldeira.kamylla@gmail.com
-
Principal Investigator:
- Kathia Cristina Abadalla
-
São Paulo, Brazil, 01508-010
- Not yet recruiting
- Fundacao Antonio Prudente - A.C.Camargo Cancer Center
-
Contact:
- Phone Number: +55 11 98565-9911
- Email: tiago.felismino@accamargo.org.br
-
Principal Investigator:
- Tiago Felismino
-
-
-
-
-
Shanghai, China, 200123
- Not yet recruiting
- Shanghai East Hospital
-
Principal Investigator:
- Jin Li
-
Contact:
- Phone Number: 13661222111
- Email: lijin@csco.org.cn
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Not yet recruiting
- Guangdong Provincial People's Hospitall
-
Contact:
- Phone Number: 020-81884713
- Email: madong8005@126.com
-
Principal Investigator:
- Dong Ma
-
-
Heilongjiang
-
Harbin, Heilongjiang, China
- Not yet recruiting
- Harbin Medical University - Cancer Hospital
-
Principal Investigator:
- Yuxian Bai
-
Contact:
- Phone Number: 13945095085
- Email: byxlcyj@126.com
-
-
Jilin
-
Changchun, Jilin, China, 130028
- Not yet recruiting
- Jilin Cancer Hospital
-
Principal Investigator:
- Ying Cheng
-
Contact:
- Phone Number: 0431-80596315
- Email: chengying@csco.org.cn
-
-
Shandong
-
Jinan, Shandong, China, 250117
- Not yet recruiting
- Shandong University - Shandong Cancer Hospital
-
Contact:
- Phone Number: 15318816098
- Email: dangqi123456@126.com
-
Principal Investigator:
- Qi Dang
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Not yet recruiting
- West China Hospital- Sichuan University
-
Contact:
- Phone Number: 18980605963
- Email: caodan@wchscu.cn
-
Principal Investigator:
- Dan Cao
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310016
- Not yet recruiting
- Sir Run Run Shaw Hospital, Zhejiang University
-
Principal Investigator:
- Hongming Pan
-
Contact:
- Phone Number: 13605716662
- Email: shonco@sina.com
-
-
-
-
-
Bologna, Italy, 40138
- Recruiting
- Policlinico S. Orsola-Malpighi
-
Principal Investigator:
- Giovanni Brandi
-
Contact:
- Phone Number: 0039 051 636 3838
- Email: giovanni.brandi@unibo.it
-
Rozzano, Italy, 20089
- Not yet recruiting
- IRCCS Humanitas Research Hospital
-
Principal Investigator:
- Lorenza Rimassa
-
Contact:
- Phone Number: 0039 0282244573
- Email: lorenza.rimassa@hunimed.eu
-
Verona, Italy, 37134
- Not yet recruiting
- AOUI Verona - Ospedale Borgo Roma
-
Principal Investigator:
- Davide Melisi
-
Contact:
- Phone Number: 8120 0039 045 812 8174
- Email: davide.melisi@gmail.com
-
-
-
-
-
Kashiwa-Shi, Japan, 277-0882
- Recruiting
- National Cancer Center Hospital East
-
Contact:
- Phone Number: 81958197200
- Email: kazuowat@east.ncc.go.jp
-
Principal Investigator:
- Susumu Watanabe
-
Nagasaki-shi, Japan, 852-8501
- Not yet recruiting
- Nagasaki University Hospital
-
Principal Investigator:
- Susumu Eguchi
-
Contact:
- Susumu Eguchi
- Phone Number: 0081 4 7133 1111
- Email: Sueguchi@nagasaki-uc.ac.jp
-
Nagoya-shi, Japan, 466-8560
- Recruiting
- Nagoya University Hospital
-
Principal Investigator:
- Takashi Mizuno
-
Contact:
- Phone Number: 0081 52 741-2111
- Email: tmzn@med.nagoya-u.ac.jp
-
Osaka-Fu, Japan, 558-8585
- Recruiting
- Osaka Metropolitan University Hospital
-
Principal Investigator:
- Hiroji Shinkawa
-
Contact:
- Phone Number: 0081 6 6645 2121
- Email: m1297198@msic.med.osaka-cu.ac.jp
-
-
Miyagi
-
Sendai, Miyagi, Japan, 980-8574
- Not yet recruiting
- Tohoku University Hospital
-
Contact:
- Phone Number: 0081 22 717 7000
- Email: maeda.shimpei@surg.med.tohoku.ac.jp
-
-
-
-
-
Busan, Korea, Republic of, 49201
- Recruiting
- Dong-A University Hospital
-
Principal Investigator:
- Sung Yong Oh
-
Contact:
- Phone Number: 82 825124028
- Email: drosy@dau.ac.kr
-
Busan, Korea, Republic of, 48108
- Recruiting
- Inje University Haeundae Paik Hospital
-
Principal Investigator:
- Il Hwan Kim
-
Contact:
- Phone Number: +82 51 797 0009
- Email: onelement@daum.net
-
Daegu, Korea, Republic of, 41944
- Recruiting
- Kyungpook National University Hospital
-
Principal Investigator:
- Won young Tak
-
Contact:
- Phone Number: 82 200-5519
- Email: wytak@knu.ac.kr
-
Jinju, Korea, Republic of, 52727
- Recruiting
- Gyeongsang National University Hospital
-
Principal Investigator:
- Jung Hun Kang
-
Contact:
- Phone Number: +82 55 750 8053
- Email: newatp@naver.com
-
Seongnam, Korea, Republic of, 13532
- Recruiting
- CHA Bundang Medical Center
-
Principal Investigator:
- Hongjae Chon
-
Contact:
- Phone Number: +82 31 780 5000
- Email: hongjaechon@gmail.com
-
Seoul, Korea, Republic of, 03722
- Recruiting
- Yonsei University Health System - Severance Hospital
-
Principal Investigator:
- Hye Jin Choi
-
Contact:
- Phone Number: +82 2 2228 8133
- Email: choihj@yuhs.ac
-
Seoul, Korea, Republic of, 06591
- Recruiting
- The Catholic University of Korea, St. Mary's Hospital
-
Contact:
- Phone Number: 82 22586044
- Email: angelamd@catholic.ac.kr
-
Principal Investigator:
- Myung Ah Lee
-
-
-
-
-
Koszalin, Poland, 75-581
- Not yet recruiting
- Szpital Wojewdzki w Koszalinie im. Mikoaja Kopernika
-
Principal Investigator:
- Piotr Wysocki
-
Contact:
- Phone Number: 0048 123516700
- Email: piotr.wysocki@uj.edu.pl
-
Lublin, Poland, 20-0920
- Recruiting
- Centrum Onkologii Ziemi Lubelskiej im. w. Jana z Dukli
-
Principal Investigator:
- Agata Chrzanowska-Kapica
-
Contact:
- Phone Number: 0048 600 238 474
- Email: achrzanowska@cozl.eu
-
Otwock, Poland, 05-400
- Not yet recruiting
- Europejskie Centrum Zdrowia Otwock Sp. Z.o.o.
-
Principal Investigator:
- Cezary Szcylik
-
Contact:
- Phone Number: +48 227 103 035
- Email: cezary.szczylik@ecz-otwock.pl
-
Warszawa, Poland, 02-034
- Recruiting
- Centrum Onkologii-Instytut im. Marii Skłodowskiej - Curie
-
Principal Investigator:
- Lucjan Wyrwicz
-
Contact:
- Phone Number: 0048 506159219
- Email: lucjan.wrywicz@nio.gov.pl
-
-
-
-
-
Lisboa, Portugal, 1400-038
- Not yet recruiting
- Fundação Champalimaud
-
Principal Investigator:
- Nuno Couto
-
Contact:
- Phone Number: 4085 00351 210 480 048
- Email: nuno.couto@fundacaochampalimaud.pt
-
Lisbon, Portugal, 1649-035
- Recruiting
- Centro Hospitalar Lisboa Norte CHLN EPE - Hospital de Santa Maria
-
Principal Investigator:
- Catarina Abreu
-
Contact:
- Phone Number: 00351 966 512 445
- Email: g.nogueiradacosta@gamil.com
-
-
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Vall d'Hebron
-
Contact:
- Phone Number: 34-914-269394
- Email: tmacarulla@gmail.com
-
Principal Investigator:
- Teresa Macarulla Mercade
-
Barcelona, Spain, 08908
- Recruiting
- Institut Català d'Oncologia de l'Hospitalet de Llobregat - Hospital Duran i Reynals
-
Contact:
- Phone Number: 34-260
- Email: blaquente@iconcologia.net
-
Principal Investigator:
- Berta Laquente Saez
-
Madrid, Spain, 28007
- Recruiting
- Hospital General Universitario Gregorio Marañón
-
Principal Investigator:
- Andres J. Munoz Martin
-
Contact:
- Phone Number: 0034 91 586 81 61
-
Madrid, Spain, 28040
- Recruiting
- Hospital Universitario Fundacion Jimenez Diaz
-
Principal Investigator:
- Angela Lamarca
-
Contact:
- Phone Number: +34 648444925
- Email: angela.lamarca@quironsalud.es
-
Madrid, Spain, 28043
- Recruiting
- Hospital Universitario 12 de Octubre
-
Contact:
- Phone Number: 34-908-926
- Email: drcofi@hotmail.com
-
Principal Investigator:
- Jorge Adeva Alfonso
-
Madrid, Spain, 28027
- Recruiting
- Clinica Universidad de Navarra, Medical Oncology Service (Mariano Ponz Sarvise)
-
Principal Investigator:
- Mariano Ponz-Sarvise
-
Contact:
- Phone Number: 7501 0034913531920
- Email: mponz@unav.es
-
Pamplona, Spain, 31008
- Recruiting
- Clínica Universidad de Navarra
-
Contact:
- Phone Number: 34-255 400
- Email: eecc@unav.es
-
Principal Investigator:
- Mariano Ponz-Sarvise
-
-
-
-
California
-
La Jolla, California, United States, 92093
- Not yet recruiting
- University of California San Diego UCSD - Moores Cancer Center
-
Principal Investigator:
- Burgoyne Adam
-
Contact:
- Phone Number: 858-657-7000
- Email: aburgoyne@health.ucsd.edu
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Recruiting
- Henry Ford Health System
-
Contact:
- Phone Number: 888-734-5322
- Email: pphilip1@hfhs.org
-
Principal Investigator:
- Philip Philip
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Recruiting
- Gabrail Cancer Center Research
-
Principal Investigator:
- Nashat Gabrail
-
Contact:
- Phone Number: 440-492-3345
- Email: nashgabrailmd@gabrailcancercenter.com
-
-
Texas
-
Abilene, Texas, United States, 79606-5208
- Recruiting
- Texas Oncology
-
Contact:
- Phone Number: 325-692-0188
- Email: anton.melnyk@usoncology.com
-
Principal Investigator:
- Melynk Anton
-
Dallas, Texas, United States, 75203
- Recruiting
- The Liver Institute at Methodist Dallas Medical Center
-
Principal Investigator:
- Parvez Mantry
-
Contact:
- Phone Number: 214-947-4450
- Email: ParvezMantry@mhd.com
-
Houston, Texas, United States, 77030
- Recruiting
- Center for Oncology and Blood Disorders
-
Principal Investigator:
- Camacho Luis
-
Contact:
- Email: lhcamacho@cobd.us
-
Contact:
- Phone Number: 833-254-6829
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically or cytologically confirmed, locally advanced, metastatic, or unresectable intrahepatic of extrahepatic Cholangiocarcinoma.
- Documented evidence of FGFR2 gene fusions or other FGFR2 rearrangement
- Received at least one prior systemic gemcitabine and platinum-based regimen for CCA
- Documentation of radiographic disease progression on the most recent prior therapy
- Measurable disease
- performance status 0 or 1
- Adequate organ function
Exclusion Criteria:
- History or current evidence of calcium and phosphate homeostasis disorder
- Current evidence of clinically significant retinal disorder
Treatment with any of the following within the specified time frame prior to the first dose of futibatinib:
- Major surgery within the previous 4 weeks (the surgical incision should be fully healed prior to the first dose of futibatinib) and radiotherapy for extended field within 4 weeks or limited field radiotherapy within 2 weeks
- Patients with locoregional therapy, eg, transarterial chemoembolization (TACE), selective internal radiotherapy (SIRT) or ablation within 4 weeks
- Any non investigational anticancer therapy within 3 weeks or have not recovered from side effects of such therapy prior to futibatinib. Endocrine therapy is allowed for patients with breast or prostate cancer
- Targeted therapy or immunotherapy within 3 weeks or within 5 half lives Any investigational agent received within 5 half-lives of the drug or 4 weeks, whichever is shorter.
- Patients with prior FGFR-directed therapy
A serious illness or medical condition(s) including (but not limited to) the following:
- Known brain metastasis (not including primary brain tumors) unless patient is clinically stable for ≥1 month
- Known acute systemic infection
- Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure (New York Heart Association [NYHA] Class III or IV New York Heart Association [NYHA] Classification) within the previous 2 months; if >2 months, cardiac function must be within normal limits and the patient must be free of cardiac-related symptoms
- Significant gastrointestinal disorder(s) that could interfere with the absorption of futibatinib.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the judgment of the Investigator would make the patient inappropriate for entry into this study.
- Known additional malignancy that is progressing or requires active treatment, with the exception of patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or antitumor assessment of the investigational regimen. Exceptions must be discussed with the Sponsor prior to patient enrollment.
- Pregnant or lactating female.
- Known hypersensitivity or severe reaction to futibatinib or its excipients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Arm A
TAS-120 (20mg) tablets, oral; 21-day cycle
|
TAS-120 is an oral FGFR inhibitor
Other Names:
|
Experimental: Treatment Arm B
TAS-120 (16mg) tablets, oral; 21-day cycle
|
TAS-120 is an oral FGFR inhibitor
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR by independent central review
Time Frame: 12 months after the study completion
|
defined as the proportion of patients experiencing a best overall response of partial response (PR) or complete response (CR) (per RECIST 1.1), based on ICR
|
12 months after the study completion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DoR by independent review
Time Frame: up to 12 months after the study completion
|
defined as time from the first documentation of response to the first documentation of objective tumor progression by ICR (per RECIST 1.1) or death due to any cause, whichever occurs first
|
up to 12 months after the study completion
|
PFS by independent review
Time Frame: up to 12 months after the study completion
|
defined as the time from date of randomization to the date of documentation of disease progression by ICR per RECIST (version 1.1, 2009) or date of death, whichever comes first
|
up to 12 months after the study completion
|
ORR per Investigator assessment
Time Frame: up to 12 months after the study completion
|
defined as proportion of patients experiencing a best overall response of partial response (PR) or complete response (CR) (per RECIST v1.1).
|
up to 12 months after the study completion
|
DoR per Investigator assessment
Time Frame: up to 12 months after the study completion
|
defined as time from the first documentation of response to the first documentation of objective tumor progression or death due to any cause, whichever occurs first
|
up to 12 months after the study completion
|
PFS per Investigator assessment
Time Frame: up to 12 months after the study completion
|
defined as the time from date of randomization to the date of disease progression based on Investigator assessment of radiographic images or death, whichever occurs first
|
up to 12 months after the study completion
|
OS
Time Frame: up to 12 months after the study completion
|
defined as the time from the date of randomization until the date of death due to any cause.
|
up to 12 months after the study completion
|
Treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0
Time Frame: up to 12 months after the study completion
|
Safety will be assessed based on reported AEs (including SAEs), graded by CTCAE V5.0.
including serious adverse events (SAEs) and dose modifications.
|
up to 12 months after the study completion
|
Change from Baseline in Quality of life as assessed by EORTC QLQ-C30
Time Frame: up to 12 months after the study completion
|
Change from Baseline in quality of life as assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score
|
up to 12 months after the study completion
|
Change from Baseline in Quality of life as assessed by EuroQol-5D (EQ-5D )
Time Frame: up to 12 months after the study completion
|
Change from Baseline in Quality of Life as Assessed by European Quality of Life - 5 Dimensions-3 Levels (EQ-5D-3L) Scale Score.
|
up to 12 months after the study completion
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TAS-120-205
- 2023-503665-39 (EudraCT Number)
- 2022-9400 (Other Identifier: Japan PMDA CTN Receipt Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cholangiocarcinoma
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)TerminatedMetastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma | Advanced CholangiocarcinomaUnited States
-
AIO-Studien-gGmbHServierCompletedCholangiocarcinoma Non-resectable | Cholangiocarcinoma of the Gallbladder | Cholangiocarcinoma Metastatic | Cholangiocarcinoma AdvancedGermany
-
Fudan UniversityRecruitingAdvanced Intrahepatic CholangiocarcinomaChina
-
HutchmedRecruitingAdvanced Intrahepatic CholangiocarcinomaChina
-
Institut de Recherches Internationales ServierCompletedMetastatic Cholangiocarcinoma | Advanced CholangiocarcinomaUnited States, Spain, Korea, Republic of, Italy, France, United Kingdom
-
National Science and Technology Development Agency...Khon Kaen UniversityUnknownAdvanced Intrahepatic CholangiocarcinomaThailand
-
Mayo ClinicNational Cancer Institute (NCI)Not yet recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic CholangiocarcinomaUnited States
-
Tyra Biosciences, IncRecruitingSolid Tumor | Intrahepatic Cholangiocarcinoma | Metastatic Cholangiocarcinoma | Locally Advanced CholangiocarcinomaUnited States
-
Aiwu Ruth He, MDMerck Sharp & Dohme LLC; Georgetown University; The Cleveland Clinic; Hoosier Cancer... and other collaboratorsTerminatedAdvanced CholangiocarcinomaUnited States
-
Jiangmen Central HospitalUnknownAdvanced CholangiocarcinomaChina
Clinical Trials on TAS-120
-
Taiho Oncology, Inc.CompletedBreast Cancer | Gastric Cancer | Cholangiocarcinoma | Urothelial Cancer | Primary CNS Tumors | Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR TumorsFrance, United States, Korea, Republic of, United Kingdom, Japan, Hong Kong, Australia, Taiwan, Italy, Canada, Germany, Netherlands, Spain
-
Taiho Oncology, Inc.Approved for marketingAdvanced CholangiocarcinomaUnited States
-
Taiho Oncology, Inc.Active, not recruitingAdvanced or Metastatic Solid Tumor | Advanced or Metastatic Gastric or Gastroesophageal Cancer | Myeloid or Lymphoid Neoplasms (MLN)United States, Spain, Turkey, Hong Kong, Korea, Republic of, Belgium, Japan, Netherlands, France, Germany, Italy, Sweden, United Kingdom, Portugal, Singapore
-
Taiho Pharmaceutical Co., Ltd.RecruitingGastric Cancer | Colorectal Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Alveolar Soft Part Sarcoma | Advanced or Metastatic Solid TumorJapan
-
Taiho Oncology, Inc.Active, not recruitingAdvanced Cholangiocarcinoma | FGFR2 Gene RearrangementsUnited States, Spain, United Kingdom, Australia, Taiwan, Italy, France, Korea, Republic of, Belgium, Japan, Thailand, Germany, Brazil, Peru, Portugal, Argentina, Hong Kong, Mexico, Netherlands, Poland
-
Taiho Pharmaceutical Co., Ltd.Completed
-
Taiho Pharmaceutical Co., Ltd.Completed
-
Huahui HealthCompletedCOVID-19 Respiratory InfectionAustralia
-
Vall d'Hebron Institute of OncologyTaisho Pharmaceutical Co., Ltd.; Roche Pharma AG; Iqvia Pty Ltd; Janssen, LPRecruitingAdvanced Solid TumorSpain, France, Germany, Netherlands, Sweden, United Kingdom, Italy
-
The University of Hong KongTaiho Pharmaceutical Co., Ltd.Active, not recruiting